Akebia Therapeutics (AKBA) Stock Forecast & Price Target

Akebia Therapeutics is attractive because Vafseo now has a differentiated commercial setup in the U.S. dialysis market, with nearly 100% contract coverage, the only oral and non-ESA option for CKD anemia, and access to roughly 290,000 dialysis patients, while VOICE showed non-inferiority and superiority versus ESAs with fewer hospitalizations. The thesis is further supported by the prospect of Vafseo becoming a standard-of-care therapy as adoption expands at dialysis organizations, especially given the reimbursement framework and the potential for convenient three-times-weekly dosing. Beyond Vafseo, the pipeline adds longer-term upside through AKB-097, which targets large kidney disease populations such as ~160,000 IgAN patients and 100,000 LN patients in the U.S., with initial Phase 2 data expected in 2027 and a potentially safer, tissue-targeted mechanism.

Akebia Therapeutics is facing a structurally weak fundamental outlook because its disclosed pipeline progress remains early and highly uncertain, with AKB-097 only in Phase 1 and the single 450mg SC dose merely advancing to Phase 2 rather than proving clinical efficacy. Although the study showed acceptable tolerability and minimal immunogenicity, the data are still limited to pharmacokinetics and pharmacodynamics, which do not offset the high failure risk that typically surrounds early-stage development. The additional mention of praliciguat only in preclinical studies reinforces that the company remains dependent on assets far from commercialization, leaving it vulnerable to execution setbacks and an unproven long-term growth profile.